Aruka Bio’s

R&D Roadmap

Formulating target-specific cancer solutions

ADCs have significantly impacted the lives of cancer patients, gaining approvals for both solid tumors and hematological malignancies. Despite their effectiveness, some patients fail to respond to ADCs for a variety of reasons. Additionally, ADCs can cause toxicities, which hinder the full realization of Ehrlich’s “magic bullet” concept. The field has been limited by the belief that a few linker payloads are suitable for all tumor targets, leading to a “one size fits all” mindset.

At Aruka, we recognize the uniqueness of each tumor target, necessitating specific ADC characteristics tailored to factors like cancer type, expression levels on tumor and normal cells, target internalization and trafficking. We believe in optimizing antibodies, linkers, and payloads for individual targets. Leveraging our medicinal chemistry expertise, we have built a vast library of proprietary linker payloads. Paired with our high throughput screening capabilities, this enables us to design and test ADCs optimized for each cancer target.